Increasing prevalence of scleroderma and rising incidences of genetic mutations coupled with drastic changes in environment is the high impact rendering divers for scleroderma diagnostics and therapeutics market. According to International reports from Japan and Britain, prevalence of systemic scleroderma is around 35 cases per 1 million adults. Women are four times more prone to develop systemic scleroderma than men. In addition, presence of high unmet medical needs and the subsequent introduction of new products catering to these needs are expected to serve this market as future growth opportunities.
Diffuse scleroderma and limited scleroderma are the types of scleroderma. Laboratory tests are used for the detection of antibodies associated with scleroderma such as antitopoisomerase antibodies (anti-scl70), anti-U3 and anticentromere antibodies A complete metabolic panel, complete blood count, thyroid function test, muscle enzymes and urinalysis are indicated for patients with scleroderma. Calcium channel blockers, alpha blockers, local nitrates, statins, serotonin receptor antagonists, angiotensin II receptor inhibitors and other drugs such as azathioprine, tetracycline antibiotics, prostanoids, cyclophosphamide and prokinetics are used for the treatment of scleroderma.
Geographically, the chemotherapy induced nausea and vomiting therapeutics market is segmented into North America, Europe, Asia Pacific, Latin America, Miidle East & Africa. North America in the most matured region of this market. Presence of favorable government regulations and funding programs coupled with high market penetration rates coupled is the major driver for regional market growth. Moreover, presence of an extensive number of clinical trials aimed at enhancing efficacy and new product development in the region is expected to fuel future market growth. Asia Pacific emerged as the fastest growing region owing to a large presence of unmet patient needs and the consequent rise in usage rates. Furthermore, presence of favorable government initiatives in Japan and Australia is expected to drive market growth during the forecast period.
Key market players for this market include Active Biotech AB, Angion Biomedica Corp., Allergan, Inc., BioLineRx, Ltd., Bayer AG, Bristol-Myers Squibb Company, Corbus pharmaceuticals, Inc., Digna Biotech, S.L., Daval International Ltd., F. Hoffmann-La Roche Ltd., Dynavax Technologies Corporation, GlaxoSmithKline plc, Fibrocell Science, Inc., MedImmune, LLC, iBio, Inc., Vida Therapeutics Inc., NovaLead Pharma Pvt. Ltd. and VivaCell Biotechnology Espana S.L.
Avail customized purchase options to meet your research needs:
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.